Trial Profile

A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients With Friedreich's Ataxia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Sep 2020 Status changed from active, no longer recruiting to completed.
08 Oct 2019 According to a Minoryx Therapeutics media release, Prof. Alexandra Durr, (Brain and Spine Institute of La Pitie-Salpetriere University Hospital (ICM), Paris) is the principal investigator and coordinator of this trial.
08 Oct 2019 According to a Minoryx Therapeutics media release, the company looks forward to completing treatment of all patients in this study and reporting on the data, which is expected by the end of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com